Cargando…

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

BACKGROUND: Limited data exist on safe discontinuation of antiprogrammed cell death protein 1 (PD-1) therapy in responding patients with advanced melanoma. The use of 18fluorodeoxyglucose ((18)FDG)-PET/CT scan and tumor biopsy for assessment of active disease may be an effective predictive biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibney, Geoffrey T., Zaemes, Jacob, Shand, Shelly, Shah, Neil J., Swoboda, David, Gardner, Kellie, Radfar, Arash, Petronic-Rosic, Vesna, Reilly, Michael J., Al-Refaie, Waddah B., Rapisuwon, Suthee, Atkins, Michael B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488718/ https://www.ncbi.nlm.nih.gov/pubmed/34599027 http://dx.doi.org/10.1136/jitc-2021-002955

Ejemplares similares

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy
por: Hwang, Michael, et al.
Publicado: (2022)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
por: Qin, Yong, et al.
Publicado: (2020)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
por: Lu, Benjamin Y, et al.
Publicado: (2021)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
por: Magahis, Patrick T, et al.
Publicado: (2023)

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
por: Ricciuti, Biagio, et al.
Publicado: (2021)

Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia
por: Gilbert, Julie R, et al.
Publicado: (2022)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
por: Mu, Wei, et al.
Publicado: (2021)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group
por: Erbe, Amy K, et al.
Publicado: (2023)

Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab
por: Jazieh, Khalid, et al.
Publicado: (2022)

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
por: Wagner, Nikolaus B, et al.
Publicado: (2021)

Single-cell analysis reveals clonally expanded tumor-associated CD57(+) CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
por: Fehlings, Michael, et al.
Publicado: (2022)

PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin
por: Canals Hernaez, Diana, et al.
Publicado: (2020)

Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens
por: Khazan-Kost, Sofia, et al.
Publicado: (2022)

DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma
por: Filipski, Katharina, et al.
Publicado: (2021)

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
por: Klümper, Niklas, et al.
Publicado: (2022)

Non-invasive PD-L1 quantification using [(18)F]DK222-PET imaging in cancer immunotherapy
por: Mishra, Akhilesh, et al.
Publicado: (2023)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
por: Chen, Di, et al.
Publicado: (2020)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
por: Nasca, Vincenzo, et al.
Publicado: (2023)

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study
por: Wu, Shaowei, et al.
Publicado: (2023)

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2021)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes
por: Schroeder, Brett A, et al.
Publicado: (2021)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
por: Perry, Lauren M, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b0vg14i82r81m34koofpiuqcp6